Conversely, inhibiting TBX2 in breast cancer, prostate cancer, oesophageal squamous cell carcinoma and lung adenocarcinoma abrogated the expression of mesenchymal markers with reciprocal restoration of the epithelial state [38,39,42,49]. Here, TBX2 is linked to prostate carcinoma.